Disease · MONDO_0005132

cytomegalovirus infection

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cytomegalovirus infection. Diseases, record MONDO_0005132. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005132

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cytomegalovirus infection; Open Targets
Open Targets ID: MONDO_0005132; Open Targets
Other names: CMV - Cytomegalovirus infection, CMV infection, CYTOMEGALIC INCLUSION DIS, CYTOMEGALOVIRAL DISEASE, CYTOMEGALOVIRUS INFECT, Cytomagalovirus infection, Cytomegalic Inclusion Diseases, Cytomegalic inclusion disease, Cytomegaloviral disease, unspecified, Cytomegaloviral disease, unspecified (disorder), Cytomegaloviral infection, Cytomegalovirus Infections, Cytomegalovirus infection (disorder), Cytomegalovirus infection, NOS, Cytomegalovirus infectious disease, Disease due to Cytomegalovirus, Disease, Cytomegalic Inclusion, Diseases, Cytomegalic Inclusion, HCMV, HCMV infection, Human Herpesvirus 5, INCLUSION DIS, INFECT CYTOMEGALOVIRUS, Inclusion Disease, Inclusion Disease, Cytomegalic, Inclusion Diseases, Inclusion Diseases, Cytomegalic, Infection, Cytomegalovirus, Infections, Cytomegalovirus, SALIVARY GLAND VIRUS DIS, Salivary gland virus disease, [X]Cytomegaloviral disease, unspecified, [X]Cytomegaloviral disease, unspecified (disorder); Open Targets
MeSH: D003586; MeSH
NCI Thesaurus: C53649; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 30 drugs, from EMA Human Drugs, FDA and TTD; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MARIBAVIR	CHEMBL515408	Small molecule	Approval	EMA Human Drugs, FDA and TTD	16	13	13	Drugs and targets
LETERMOVIR	CHEMBL1241951	Small molecule	Approval	EMA Human Drugs and FDA	11	7	7	Drugs and targets
CIDOFOVIR	CHEMBL5314375	Small molecule	Approval	TTD	4	2	2	Drugs and targets
FOMIVIRSEN SODIUM	CHEMBL1201512	Oligonucleotide	Approval	TTD, at withdrawal	1	0	0	Drugs and targets
REGAVIRUMAB	CHEMBL2107880	Antibody	Preapproval	TTD	1	0	0	Drugs and targets
VALGANCICLOVIR	CHEMBL1201314	Small molecule	Phase 3	ClinicalTrials.gov	17	17	17	Drugs and targets
GANCICLOVIR	CHEMBL182	Small molecule	Phase 3	ClinicalTrials.gov	14	14	14	Drugs and targets
FOSCARNET	CHEMBL666	Small molecule	Phase 3	ClinicalTrials.gov	3	2	2	Drugs and targets
ADEFOVIR DIPIVOXIL	CHEMBL922	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVOCARNITINE	CHEMBL1149	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	2	FK506-binding protein 1A inhibitor	Phase 2	https://conductscience.org/library/genes/2280	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Unknown	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Unknown	https://conductscience.org/library/genes/942	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Phase 2	https://conductscience.org/library/genes/1642	Drugs and targets
FAAH	Fatty-acid amide hydrolase 1	1	Anandamide amidohydrolase inhibitor	Phase 2	https://conductscience.org/library/genes/2166	Drugs and targets
HMGCR	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1	HMG-CoA reductase inhibitor	Unknown	https://conductscience.org/library/genes/3156	Drugs and targets
HRH1	Histamine H1 receptor	1	Histamine H1 receptor antagonist	Phase 2	https://conductscience.org/library/genes/3269	Drugs and targets
IL2RA	Interleukin-2 receptor	1	Interleukin-2 receptor agonist	Phase 1/2	https://conductscience.org/library/genes/3559	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials54

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02927067	A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants	Phase 3	553	2023-03-03	Cytomegalovirus (CMV)	MARIBAVIR	Its record names the disease	ClinicalTrials.gov
NCT02931539	Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir	Phase 3	352	2021-09-23	Cytomegalovirus (CMV)	CIDOFOVIR, FOSCARNET, GANCICLOVIR, MARIBAVIR, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT01611974	Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients	Phase 2	120	2015-12-17	Cytomegalovirus (CMV)	MARIBAVIR	Its record names the disease	ClinicalTrials.gov
NCT04840199	A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.	Phase 2	44	2025-03-04	HIV Infections, Cytomegalovirus, CMV	LETERMOVIR	Its record names the disease	ClinicalTrials.gov
NCT05137717	A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection	Phase 3	41	2024-07-09	Cytomegalovirus (CMV)	MARIBAVIR	Its record names the disease	ClinicalTrials.gov
NCT03728426	Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection	Phase 2	10	2023-03-08	Cytomegalovirus Infections	LETERMOVIR	Its record names the disease	ClinicalTrials.gov
NCT02210065	Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation	Phase 2	6	2020-03-17	Leukemia, Lymphoma	ACETAMINOPHEN, DIPHENHYDRAMINE	Its record names the disease	ClinicalTrials.gov
NCT03915366	Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia	Phase 2/3	563		Pneumonia, HIV/AIDS, Tuberculosis, Cytomegalovirus Infections	VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov
NCT00001082	The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected Patients	Phase 3	505		Cytomegalovirus Infections, HIV Infections	ADEFOVIR DIPIVOXIL, LEVOCARNITINE	Its record names the disease	ClinicalTrials.gov
NCT07286461	VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol		290		Allogeneic Hematopoietic Stem Cell Transplantation Recipient, CMV	FOSCARNET, GANCICLOVIR, LETERMOVIR, MARIBAVIR, VALGANCICLOVIR	Its record names the disease	ClinicalTrials.gov

1 to 10 of 54

See all 54 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: deaths from any cause	29 of 277	37 of 276	553	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at the End of Week 8, Followed by Maintenance of Treatment Effect at Week 16	133 of 274	144 of 273	547	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribose Nucleic Acid (DNA) at the End of Study Week 8	212 of 274	190 of 273	547	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Developing Resistance	8 of 274	24 of 273	547	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants Who Achieved Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at Week 8 After Receiving 8 Weeks of Study Assigned Treatment	137 of 274	158 of 273	547	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Treatment-Emergent Adverse Events During the On-Treatment Period	269 of 274	268 of 273	547	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: serious adverse events	95 of 274	88 of 273	547	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Confirmed Recurrence of Viremia During the Follow-up Period	47 of 236	27 of 226	462	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Confirmed Recurrence of Viremia at Any Time During the Study	53 of 236	43 of 226	462	NCT02927067	Trial comparisons
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: Number of Participants With Confirmed Recurrence of Viremia During First 8 Weeks of the Study	6 of 236	16 of 226	462	NCT02927067	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials31

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29067253	RESULT	1	PubMed
16780548	RESULT	1	PubMed
42468541	DERIVED	1	PubMed
42283791	DERIVED	1	PubMed
42016921	DERIVED	1	PubMed
41403238	DERIVED	1	PubMed
41384277	DERIVED	1	PubMed
40478680	DERIVED	1	PubMed
40307889	DERIVED	1	PubMed
39807668	DERIVED	1	PubMed

1 to 10 of 31

See all 31 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005132

GET https://conductscience.org/api/diseases/v1/MONDO_0005132/drugs?page=2

API reference For AI assistants